31 Mar 2020
Assets22.45
Total Income39.42
Profit After Tax0.93
NET Worth4.25
Reserves and Surplus0.00
Total Borrowing5.66
At a glance
Updated 2026-09-17Infinium Pharmachem is a SME IPO with an issue size of ₹25.25 crore, proposed for listing on NSE SME. The issue structure includes a fresh issue of ₹23.99 crore.
Issue details
Listing atNSE SME
Issue typeFixed Price Issue
Issue size₹25.25 Cr
Fresh issue₹23.99 Cr
Face value₹10
Price band—–—
Grey market
GMP page ↗Latest GMP₹2.00
GMP / upper priceNO DATA
Est. listing₹137.00
GMP is unofficial sentiment data, not an exchange price.
Subscription demand
Full bidding ↗NO DATAWaiting for a verified live exchange update.
Company
Use of proceeds
| Object | Amount |
|---|---|
| Marketing and Branding Expenses (including Registration in Reach - Europe, other marketing expenses) | ₹1.13 Cr |
| Repayment of some of Existing Loans; | ₹3.92 Cr |
| Expansion of Existing Unit | ₹5.05 Cr |
| To Meet Incremental Working Capital Requirements; | ₹10.10 Cr |
| General Corporate Purpose | ₹4.43 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue79.85₹ Cr · -20.2% vs prior year
PAT5.51₹ Cr · -9.8% vs prior year
Assets70.76₹ Cr · +19.9% vs prior year
Net Worth18.56₹ Cr · +41.7% vs prior year
Borrowing16.15₹ Cr · +16.6% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2021
Assets34.18
Total Income71.15
Profit After Tax2.72
NET Worth7.02
Reserves and Surplus0.00
Total Borrowing5.79
31 Mar 2022
Assets59.00
Total Income100.05
Profit After Tax6.11
NET Worth13.10
Reserves and Surplus0.00
Total Borrowing13.85
30 Sep 2022
Assets70.76
Total Income79.85
Profit After Tax5.51
NET Worth18.56
Reserves and Surplus0.00
Total Borrowing16.15
KPIs
| KPI | Mar 31, 2022 |
|---|---|
| ROE | 43.85% |
| ROCE | 72% |
| Debt / Equity | 2.91% |
| RoNW | 46.61% |
| PAT Margin | 6.16% |
| EBITDA Margin | 11.06% |
Valuation & shareholding
Pre-IPO EPS54.13
Pre-IPO P/E7.83
Promoter holding pre100%
Promoter holding post73.05%
Market cap₹93.93 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Infinium Pharmachem IPO | — | 7.83 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Lead Manger Fees including Underwriting Commission | ₹0.25 Cr |
| Fees Payable to Registrar to the Issue | ₹0.01 Cr |
| Fees Payable Advertising, Marketing Expenses and Printing Expenses | ₹0.25 Cr |
| Fees Payable to Regulators including Stock Exchanges and other Intermediaries | ₹0.04 Cr |
| Fees payable to Peer Review Auditor, Legal Advisor and Other Professional | ₹0.03 Cr |
| Fees Payable to Market Maker (for Two Years). | ₹0.05 Cr |
| Escrow Bank Fees | ₹0.00 Cr |
Registrar & lead managers
Registrar
Bigshare Services Pvt.Ltd.Lead managers
- Swastika Investmart Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-17.
IPO UPDATE ALERTS
Register for IPO Updates →Track Infinium Pharmachem without missing an update
Register for subscription, GMP, allotment and listing notifications.